



(51) International Patent Classification:

A61K 31/195 (2006.01) *A61P 3/14* (2006.01)

(21) International Application Number:

PCT/US2021/050677

(22) International Filing Date:

16 September 2021 (16.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:



63/080,165 18 September 2020 (18.09.2020) US
63/159,397 10 March 2021 (10.03.2021) US(71) Applicant: **CALCILYTIX THERAPEUTICS, INC.**
[US/US]; 1800 Owens St., Ste. C-1200, San Francisco, California 94158 (US).(72) Inventors: **BRUCE, Simon**; c/o Calcilytix Therapeutics, Inc., 1800 Owens St., Ste. C-1200, San Francisco, California 94158 (US). **FOX, Jonathan**; c/o Calcilytix Therapeutics, Inc., 1800 Owens St., Ste. C-1200, San Francisco, California 94158 (US). **SANI-GROSSO, Ramei**; c/o Calcilytix Therapeutics, Inc., 1800 Owens St., Ste. C-1200, San Francisco, California 94158 (US). **KOMEYLI, Ali**; c/o Calcilytix Therapeutics, Inc., 1800 Owens St., Ste. C-1200, San Francisco, California 94158 (US). **SRIDHAR, Ananth**; c/o Calcilytix Therapeutics, Inc., 1800 Owens St., Ste. C-1200,San Francisco, California 94158 (US). **ROBERTS, Mary Scott**; c/o Calcilytix Therapeutics, Inc., 1800 Owens St., Ste. C-1200, San Francisco, California 94158 (US).(74) Agent: **DONG, Yaohua** et al.; Mintz Levin Cohn Ferris Glovsky & Popeo, P.C., One Financial Center, Boston, Massachusetts 02111 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: TRIPHENYL CALCILYTIC COMPOUNDS FOR THE TREATMENT OF AUTOSOMAL DOMINANT HYPOCALCEMIA TYPE 1 (ADH1)

FIG. 9A



(57) **Abstract:** The present disclosure provides a method of treating an autosomal dominant hypocalcemia type 1 (ADH1) with a therapeutically effective amount of a compound of formula (I), in particular CLTX-305, wherein the therapeutically effective amount of the compound increases a blood calcium concentration (cCa) to a range of about 7.5 mg/dL to about 10.5 mg/dL, such as about 8.5 mg/dL to about 10.5 mg/dL. Also provided herein is a dosing finding method for treating an autosomal dominant hypocalcemia type 1 (ADH1) with a therapeutically effective amount of a compound of formula (I) or CLTX-305 according to one or more dosing regimens.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*